Changeflow GovPing Healthcare & Life Sciences Process for the production of levetiracetam
Routine Notice Added Final

Process for the production of levetiracetam

Favicon for changeflow.com USPTO Patent Grants - Organic Chemistry (C07D)
Published
Detected
Email

Summary

USPTO granted Patent US12590059B2 to Suzhou BrightHope Pharmatech Co., Ltd. for a process to produce levetiracetam via crystallization in aqueous solution, resulting in a product containing no residual organic solvent. The patent lists 4 inventors (Songzhou Hu, Lijun Deng, Wen Yu, Zhen Song) and contains 13 claims under classification C07D 207/27.

Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

USPTO issued Patent No. US12590059B2 to Suzhou BrightHope Pharmatech Co., Ltd. on March 31, 2026, covering a novel process for producing levetiracetam through crystallization in an aqueous solution, optionally with a water-soluble solvent. The process yields levetiracetam with no residual organic solvent. The application (No. 18210330) was filed on June 15, 2023, and the patent contains 13 claims classified under C07D 207/27.

Pharmaceutical manufacturers and generic drug producers should review this patent to ensure their levetiracetam production processes do not infringe on the granted claims. This is an informational patent grant conferring exclusivity rights to the assignee; no compliance actions or deadlines are triggered by this notice.

Archived snapshot

Mar 31, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Grants

Process for the production of levetiracetam

Grant US12590059B2 Kind: B2 Mar 31, 2026

Assignee

SUZHOU BRIGHTHOPE PHARMATECH CO., LTD

Inventors

Songzhou Hu, Lijun Deng, Wen Yu, Zhen Song

Abstract

There is disclosed a process for the production of levetiracetam by crystallizing levetiracetam in an aqueous solution, optionally in the presence of a water-soluble solvent. The product of levetiracetam contains no residual organic solvent.

CPC Classifications

C07D 207/27

Filing Date

2023-06-15

Application No.

18210330

Claims

13

View original document →

Get daily alerts for USPTO Patent Grants - Organic Chemistry (C07D)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
March 31st, 2026
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
US12590059B2

Who this affects

Applies to
Pharmaceutical companies Manufacturers
Industry sector
3254 Pharmaceutical Manufacturing
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal

Get alerts for this source

We'll email you when USPTO Patent Grants - Organic Chemistry (C07D) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!